DB Name	Query	Hit Count	Set Name
USPT,JPAB,EPAB,DWPI,TDBD	L10 and (autoimmune disease)	13	L11
USPT,JPAB,EPAB,DWPI,TDBD	(ds oligonucleotide)	130	L10
USPT,JPAB,EPAB,DWPI,TDBD	Rice-john-m$.in.	7	L9
USPT,JPAB,EPAB,DWPI,TDBD	Kohn-leonard-d$.in.	3	L8
USPT,JPAB,EPAB,DWPI,TDBD	L5 and (ds polynucleotide)	0	L7
USPT,JPAB,EPAB,DWPI,TDBD	L5 and (MHC)	25	L6
USPT,JPAB,EPAB,DWPI,TDBD	L1 and (autoimmune disease)	111	L5
USPT,JPAB,EPAB,DWPI,TDBD	L1 and ((MHC gene) or (TAP-1 or TAP-2) or PKR or JAK or STAT)	33	L4
USPT,JPAB,EPAB,DWPI,TDBD	L1 and (immune recognition)	8	L3
USPT,JPAB,EPAB,DWPI,TDBD	L1 and ((MHC gene) adj expression)	2	L2
USPT,JPAB,EPAB,DWPI,TDBD	(ds RNA) or (ds DNA)	1415	L1

```
S16          5   S1 AND (ANTIGEN (W) PRESENTATION)
S17          3   RD (unique items)
S18          0   S1 AND (NON (W) SPECIFIC (W) SEQUENCE)
S19        355   S1 AND (VACCINE OR TREATMENT OR IMMUNOTHERAPY)
S20        203   RD (unique items)
S21          0   S20 AND (ENHANCED (W) IMMUNE (W) RESPONSE)
S22          4   S20 AND (REVIEW)
S23          0   AU=(KOHN, L?) OR (KOHN L?)
S24          0   AU=(KOHN, LEONARD) OR (KOHN LEONARD)
S25          3   AU=(SUZUKI, K?) OR (SUZUKI K?)
S26          3   RD (unique items)
?s s25 and s20
               3  S25
             203  S20
     S27       0  S25 AND S20
?ds

Set     Items   Description
S1       2608   (DS (W) (RNA OR DNA OR OLIGONUCLEOTIDE OR POLYNUCLEOTIDE OR
            PLASMID))
S2          3   S1 AND (MHC (W) GENE)
S3          1   RD (unique items)
S4        120   S1 AND (TAP-1 OR TAP-2 OR PKR OR IFNBETA OR MAP OR JAK OR -
            STAT)
S5          0   S4 AND (ANITGEN (W) PRESENTATION)
S6          0   S4 AND (ANTIGEN (W) PRESENTATION)
S7          0   S4 AND (AUTOIMMUNE (W) DISEASE)
S8          0   S4 AND (AUTOIMMUNE)
S9          0   S4 AND (IMMUNE (W) RECOGNITION)
S10         0   S4 AND ((ABERRANT OR ENHANCED) (W) (EXPRESSION))
S11         0   S4 AND (THYROID OR THYROCYTE)
S12         4   S1 AND (ANTIGEN (W) PRESENTING (W) CELL?)
S13         2   RD (unique items)
S14         8   S1 AND (AUTOIMMUNE (W) RESPONSE)
S15         5   RD (unique items)
S16         5   S1 AND (ANTIGEN (W) PRESENTATION)
S17         3   RD (unique items)
S18         0   S1 AND (NON (W) SPECIFIC (W) SEQUENCE)
S19       355   S1 AND (VACCINE OR TREATMENT OR IMMUNOTHERAPY)
S20       203   RD (unique items)
S21         0   S20 AND (ENHANCED (W) IMMUNE (W) RESPONSE)
S22         4   S20 AND (REVIEW)
S23         0   AU=(KOHN, L?) OR (KOHN L?)
S24         0   AU=(KOHN, LEONARD) OR (KOHN LEONARD)
S25         3   AU=(SUZUKI, K?) OR (SUZUKI K?)
S26         3   RD (unique items)
S27         0   S25 AND S20
?logoff
       13jan01 15:16:08 User259876 Session D178.2
            $6.09    1.904 DialUnits File155
               $2.20  11 Type(s) in Format  3
            $2.20  11 Types
     $8.29  Estimated cost File155
           $11.70    2.089 DialUnits File5
               $4.95  3 Type(s) in Format  3
            $4.95  3 Types
    $16.65  Estimated cost File5
           $18.04    2.123 DialUnits File73
               $9.40  4 Type(s) in Format  3
            $9.40  4 Types
    $27.44  Estimated cost File73
            OneSearch, 3 files,  6.116 DialUnits FileOS
     $1.75  TYMNET
    $54.13  Estimated cost this search
    $54.55  Estimated total session cost   6.231 DialUnits
```

```
### Status: Path 1 of [Dialog Information Services via Modem]

### Status: Initializing TCP/IP using (UseTelnetProto 1 ServiceID pto-dialog)
Trying 3106900061...Open

DIALOG INFORMATION SERVICES
PLEASE LOGON:
 ******** HHHHHHHH SSSSSSSS?
### Status: Signing onto Dialog
 ********
ENTER PASSWORD:
 ******** HHHHHHHH SSSSSSSS? ********
Welcome to DIALOG
### Status: Connected


Dialog level 00.12.12D

Last logoff:  07jan01 10:59:11
Logon file001 13jan01 14:41:20
           *** ANNOUNCEMENT ***
                  ***
NEW FILE RELEASED
***Daily and Sunday Telegraph (London) Papers (File 756)
***The Mirror Group Publications (United Kingdom) (File 757)
***Prous Science Daily Essentials (Files 458, 459)
***WIPO/PCT Patents Fulltext (File 349)

UPDATING RESUMED
***Extel News Cards from Primark (File 501)
***TFSD Ownership Database (File 540)
                           ***
RELOADED
***Kompass Central/Eastern Europe (File 593)
***Kompass Latin America (File 586)
***Brands and their Companies (File 116)
***Kompass USA (File 584)
***Kompass Canada (File 594)
***PsycINFO (File 11)
FILES REMOVED
***EconBase (File 565)
***Unlisted Drugs (File 140)

>>>Get immediate news with Dialog's First Release
   news service.  First Release updates major newswire
   databases within 15 minutes of transmission over the
   wire.  First Release provides full Dialog searchability
   and full-text features.  To search First Release files in
   OneSearch simply BEGIN FIRST for coverage from Dialog's
   broad spectrum of news wires.

     >>> Enter BEGIN HOMEBASE for Dialog Announcements <<<
     >>>    of new databases, price changes, etc.      <<<
                  ****
KWIC is set to 50.
HILIGHT set on as '*'
*** NEW Current Year Ranges Install ***

File   1:ERIC  1966-2000/Dec 05
       (c) format only 2000 The Dialog Corporation

      Set  Items  Description
      ---  -----  -----------
?b 155, 5, 73
       13jan01 14:41:38 User259876 Session D178.1
```

```
          $0.40    0.115 DialUnits File1
     $0.40  Estimated cost File1
     $0.02  TYMNET
     $0.42  Estimated cost this search
     $0.42  Estimated total session cost   0.115 DialUnits


SYSTEM:OS  - DIALOG OneSearch
  File 155:MEDLINE(R)  1966-2000/Dec W4
        (c) format only 2000 Dialog Corporation
*File 155: For information on updating, changes to the file, and
check tags information please see Help News155.
  File   5:Biosis Previews(R)  1969-2001/Jan W2
        (c) 2001 BIOSIS
  File  73:EMBASE  1974-2001/Jan W2
        (c) 2001 Elsevier Science B.V.
*File  73: For details about update codes see Help News73.

      Set  Items  Description
      ---  -----  -----------
?s (ds (w) (RNA or DNA or oligonucleotide or polynucleotide or plasmid))
           18368  DS
          829702  RNA
         1563264  DNA
           72584  OLIGONUCLEOTIDE
            8939  POLYNUCLEOTIDE
          151224  PLASMID
      S1    2608  (DS (W) (RNA OR DNA OR OLIGONUCLEOTIDE OR POLYNUCLEOTIDE
                  OR PLASMID))
?s s1 and (MHC (w) gene)
            2608  S1
           75721  MHC
         1554207  GENE
            1913  MHC(W)GENE
      S2       3  S1 AND (MHC (W) GENE)
?rd
...completed examining records
      S3       1  RD (unique items)
?t s3/3,k/all

 3/3,K/1     (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2000 Dialog Corporation. All rts. reserv.

09849984   99162596
 Activation of target-tissue immune-recognition molecules by
double-stranded polynucleotides.
  Suzuki K; Mori A; Ishii KJ; Saito J; Singer DS; Klinman DM; Krause PR;
Kohn LD
  Cell Regulation Section, Metabolic Diseases Branch, National Institute of
Diabetes and Digestive and Kidney Diseases, National Institutes of Health,
Bethesda, MD 20892, USA.
  Proceedings of the National Academy of Sciences of the United States of
America (UNITED STATES)  Mar 2 1999,  96 (5) p2285-90,  ISSN 0027-8424
Journal Code: PV3
  Languages: ENGLISH
  Document type: JOURNAL ARTICLE

  ... Autoimmune responses can be triggered by viral infections or tissue
injuries. We show that the ability of a virus or a tissue injury to
increase *MHC* *gene* expression is duplicated by any fragment of
double-stranded (*ds*) *DNA* or dsRNA introduced into the cytoplasm of
nonimmune cells. Activation is sequence-independent, is induced by ds
polynucleotides as small as 25 bp in length...
?ds
```

```
Set     Items   Description
S1       2608   (DS (W) (RNA OR DNA OR OLIGONUCLEOTIDE OR POLYNUCLEOTIDE OR
             PLASMID))
S2          3   S1 AND (MHC (W) GENE)
S3          1   RD (unique items)
?s s1 and (TAP-1 or TAP-2 or PKR or IFNbeta or MAP or JAK or STAT)
            2608  S1
              22  TAP-1
              12  TAP-2
            1225  PKR
             407  IFNBETA
          129733  MAP
            3405  JAK
           11919  STAT
      S4     120  S1 AND (TAP-1 OR TAP-2 OR PKR OR IFNBETA OR MAP OR JAK OR
                  STAT)
?s s4 and (anitgen (w) presentation)
             120  S4
              42  ANITGEN
          192579  PRESENTATION
               2  ANITGEN(W)PRESENTATION
      S5       0  S4 AND (ANITGEN (W) PRESENTATION)
?s s4 and (antigen (w) presentation)
             120  S4
          839168  ANTIGEN
          192579  PRESENTATION
           19481  ANTIGEN(W)PRESENTATION
      S6       0  S4 AND (ANTIGEN (W) PRESENTATION)
?s s4 and (autoimmune (w) disease)
             120  S4
          129000  AUTOIMMUNE
         3803231  DISEASE
           32624  AUTOIMMUNE(W)DISEASE
      S7       0  S4 AND (AUTOIMMUNE (W) DISEASE)
?s s4 and (autoimmune)
             120  S4
          129000  AUTOIMMUNE
      S8       0  S4 AND (AUTOIMMUNE)
?s s4 and (immune (w) recognition)
             120  S4
          948169  IMMUNE
          251732  RECOGNITION
            2295  IMMUNE(W)RECOGNITION
      S9       0  S4 AND (IMMUNE (W) RECOGNITION)
?s s4 and ((aberrant or enhanced) (w) (expression))
             120  S4
           41003  ABERRANT
          535608  ENHANCED
         1338049  EXPRESSION
           11074  (ABERRANT OR ENHANCED)(W)EXPRESSION
     S10       0  S4 AND ((ABERRANT OR ENHANCED) (W) (EXPRESSION))
?s s4 and (thyroid or thyrocyte)
             120  S4
          234361  THYROID
             862  THYROCYTE
     S11       0  S4 AND (THYROID OR THYROCYTE)
?ds

Set     Items   Description
S1       2608   (DS (W) (RNA OR DNA OR OLIGONUCLEOTIDE OR POLYNUCLEOTIDE OR
             PLASMID))
S2          3   S1 AND (MHC (W) GENE)
S3          1   RD (unique items)
S4        120   S1 AND (TAP-1 OR TAP-2 OR PKR OR IFNBETA OR MAP OR JAK OR -
             STAT)
S5          0   S4 AND (ANITGEN (W) PRESENTATION)
```

```
S6          0   S4 AND (ANTIGEN (W) PRESENTATION)
S7          0   S4 AND (AUTOIMMUNE (W) DISEASE)
S8          0   S4 AND (AUTOIMMUNE)
S9          0   S4 AND (IMMUNE (W) RECOGNITION)
S10         0   S4 AND ((ABERRANT OR ENHANCED) (W) (EXPRESSION))
S11         0   S4 AND (THYROID OR THYROCYTE)
?s s1 and (antigen (w) presenting (w) cell?)
Processing
Processing
            2608  S1
          839168  ANTIGEN
          175387  PRESENTING
         6743875  CELL?
           25380  ANTIGEN(W)PRESENTING(W)CELL?
     S12       4  S1 AND (ANTIGEN (W) PRESENTING (W) CELL?)
?rd
...completed examining records
     S13       2  RD (unique items)
?t s13/3,k/all
```

13/3,K/1 (Item 1 from file: 155)

DIALOG(R)File 155:MEDLINE(R)
(c) format only 2000 Dialog Corporation. All rts. reserv.

09905346 99160629

Maturation, activation, and protection of dendritic cells induced by double-stranded RNA.

Cella M; Salio M; Sakakibara Y; Langen H; Julkunen I; Lanzavecchia A
Basel Institute for Immunology, CH-4005 Basel, Switzerland. cella@bii.ch
Journal of experimental medicine (UNITED STATES) Mar 1 1999, 189 (5) p821-9, ISSN 0022-1007 Journal Code: I2V
Languages: ENGLISH
Document type: JOURNAL ARTICLE

... cytokines or for conserved patterns characteristic of infectious agents. Here we show that human DCs are activated by influenza virus infection and by double-stranded (*ds*)*RNA*. This activation results not only in increased antigen presentation and T cell stimulatory capacity, but also in resistance to the cytopathic effect of the virus, mediated by the production of type I interferon, and upregulation of MxA. Because dsRNA stimulates both maturation and resistance, DCs can serve as altruistic *antigen*-*presenting* *cells* capable of sustaining viral antigen production while acquiring the capacity to trigger naive T cells and drive polarized T helper cell type 1 responses.

13/3,K/2 (Item 2 from file: 155)

DIALOG(R)File 155:MEDLINE(R)
(c) format only 2000 Dialog Corporation. All rts. reserv.

05847563 89233254

Lupus erythematosus cell formation by a monoclonal antibody derived from an autoimmune MRL/Mp-lpr/lpr mouse.

Kanai Y; Yamauchi S; Hashiba-Kanai Y
Department of Molecular Oncology, University of Tokyo, Japan.
Immunology letters (NETHERLANDS) Jan 15 1989, 20 (1) p9-13, ISSN 0165-2478 Journal Code: GIH
Languages: ENGLISH
Document type: JOURNAL ARTICLE

... shown to cross-react with single-stranded (ss) DNA. Detailed examination revealed that MRP-2 MoAb bound to a conformational epitope formed between double-stranded (*ds*) *DNA* and total histone: both H3 and H4 were essential for the formation of this conformational epitope with dsDNA. Because of this characteristic of the MoAb...
; *Antigen*-*Presenting* *Cells*--Pathology--PA; Autoimmune Diseases

--Genetics--GE; Autoimmune Diseases--Pathology--PA; Deoxyribonucleoprotein
s--Immunology--IM; DNA--Immunology--IM; DNA--Metabolism--ME; Epitopes
--Immunology--IM; Histones--Metabolism--ME...
?ds

Set	Items	Description
S1	2608	(DS (W) (RNA OR DNA OR OLIGONUCLEOTIDE OR POLYNUCLEOTIDE OR PLASMID))
S2	3	S1 AND (MHC (W) GENE)
S3	1	RD (unique items)
S4	120	S1 AND (TAP-1 OR TAP-2 OR PKR OR IFNBETA OR MAP OR JAK OR -STAT)
S5	0	S4 AND (ANITGEN (W) PRESENTATION)
S6	0	S4 AND (ANTIGEN (W) PRESENTATION)
S7	0	S4 AND (AUTOIMMUNE (W) DISEASE)
S8	0	S4 AND (AUTOIMMUNE)
S9	0	S4 AND (IMMUNE (W) RECOGNITION)
S10	0	S4 AND ((ABERRANT OR ENHANCED) (W) (EXPRESSION))
S11	0	S4 AND (THYROID OR THYROCYTE)
S12	4	S1 AND (ANTIGEN (W) PRESENTING (W) CELL?)
S13	2	RD (unique items)

?s s1 and (autoimmune (w) response)

	2608	S1
	129000	AUTOIMMUNE
	2214457	RESPONSE
	3762	AUTOIMMUNE(W)RESPONSE
S14	8	S1 AND (AUTOIMMUNE (W) RESPONSE)

?rd
...completed examining records

S15	5	RD (unique items)

?t s15/3,k/all

15/3,K/1 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

09485917 98207352
[Immunology in medical practice. III. Disseminated lupus erythematosus: disturbed apoptosis?]
Immunologie in de medische praktijk. III Lupus erythematodes disseminatus: gestoorde apoptose?
Berden JH
Academisch Ziekenhuis, afd. Nierziekten, Nijmegen.
Nederlands tijdschrift voor geneeskunde (NETHERLANDS) Sep 27 1997, 141 (39) p1848-54, ISSN 0028-2162 Journal Code: NUK
Languages: DUTCH Summary Languages: ENGLISH
Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL ; English Abstract

The main feature of systemic lupus erythematosus (SLE) is formation of antinuclear antibodies, particularly against double-stranded (*ds*) *DNA*. This *autoimmune* *response* is T cell- and (auto)antigen-dependent, but dsDNA is very poorly immunogenic. Recent data suggest that the nucleosome is the principal autoantigen in SLE...

15/3,K/2 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

09101535 97187533
Revisiting autoantibody profiles in systemic lupus erythematosus.
Olhoffer IH; Peng SL; Craft J
Section of Rheumatology, Yale University School of Medicine, New Haven, CT, USA.
Journal of rheumatology (CANADA) Feb 1997, 24 (2) p297-302, ISSN

0315-162X Journal Code: JWX
Contract/Grant No.: AR40072, AR, NIAMS; AR42475, AR, NIAMS
Languages: ENGLISH
Document type: JOURNAL ARTICLE

... To obtain more definitive assays of the spectrum of soluble autoantigens targeted by individual patients with systemic lupus erythematosus (SLE) and to determine whether the *autoimmune* *response* is restricted in specificity. Although there are many reports of a broad spectrum of autoantibody specificities in SLE, none has considered the diversity of autoantibody sets, which may more accurately describe the *autoimmune* *response*. METHODS: Sera of 68 patients with SLE were assayed for autoantibodies by ELISA and/or immunoprecipitation. Specificities were grouped into sets, including double stranded (*ds*) *DNA* and/or histone, U1 RNP and/or Sm, Ro and/or La, ribosomes, Ku, Ki, and others. An analysis was also performed of reported SLE...

15/3,K/3 (Item 3 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

08694948 95347760
Induction of autoantibodies in normal mice by injection of nucleobindin and natural occurrence of antibodies against nucleobindin in autoimmune MRL/lpr/lpr mice.
Kanai Y; Takeda O; Miura K; Amagai M; Kaneko T; Kubota T; Kanai Y; Tanuma S; Kurosawa Y
Department of Molecular Oncology, University of Tokyo, Japan.
Immunology letters (NETHERLANDS) Feb 1995, 45 (1-2) p35-42, ISSN 0165-2478 Journal Code: GIH
Languages: ENGLISH
Document type: JOURNAL ARTICLE

Our previous works have shown that nucleobindin (Nuc) or recombinant (r) Nuc not only augments anti-DNA antibody production in vitro but also accelerates *autoimmune* *response* in vivo in MRL/+/+ (MRL/n) mice which are the substrain of autoimmune MRL/lpr/lpr (MRL/l) mice. To investigate whether rNuc can induce *autoimmune* *response* similarly in naive mice, we carried out intraperitoneal (i.p.) injection of rNuc (5 micrograms) without adjuvant into 8-week-old female BALB/c mice...

... the mice began to show IgG hypergammaglobulinemia (HG) followed by elevation of a number of autoantibodies of the IgG class such as anti-double-stranded (*ds*) *DNA* , anti-U1 ribonuclear protein (RNP), anti-ssB(La) and anti-Fc antibodies (RF), but not by anti-Sm antibodies. However, the IgG anti-dsDNA antibody...

15/3,K/4 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

07019305 EMBASE No: 1997308294
Immunology in medical practice. III. Systemic lupus erythematosus: Disturbed apoptosis?
IMMUNOLOGIE IN DE MEDISCHE PRAKTIJK. III. LUPUS ERYTHEMATODES DISSEMINATUS: GESTOORDE APOPTOSE?
Berden J.H.M.
Prof. Dr. J.H.M. Berden, Academisch Ziekenhuis, Afd. Nierziekten, Postbus 9101, 6500 HB Nijmegen Netherlands
Nederlands Tijdschrift voor Geneeskunde (NED. TIJDSCHR. GENEESKD.) (Netherlands) 1997, 141/39 (1848-1854)
CODEN: NETJA ISSN: 0028-2162
DOCUMENT TYPE: Journal; Review
LANGUAGE: DUTCH SUMMARY LANGUAGE: ENGLISH; DUTCH

NUMBER OF REFERENCES: 67

The main feature of systemic lupus erythematosus (SLL) is formation of antinuclear antibodies, particularly against double-stranded (*ds*) *DNA*. This *autoimmune* *response* is T cell- and (auto)antigen-dependent, but dsDNA is very poorly immunogenic. Recent data suggest that the nucleosome is the principal autoantigen in SLE...

15/3,K/5 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE

06068968 EMBASE No: 1995099434
Induction of autoantibodies in normal mice by injection or nucleobinin and natural occurrence of antibodies against nucleobindin in autoimmune MRL/lpr/lpr mice
Kanai Y.; Takeda O.; Miura K.; Amagai M.; Kaneko T.; Kubota T.; Kanai Y.; Tanuma S.-I.; Kurosawa Y.
Department of Molecular Oncology, Institute of Medical Science, University of Tokyo,Minato-Ku, Tokyo 108 Japan
Immunology Letters (IMMUNOL. LETT.) (Netherlands) 1995, 45/1-2 (35-42)
CODEN: IMLED ISSN: 0165-2478
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

Our previous works have shown that nucleobindin (Nuc) or recombinant (r) Nuc not only augments anti-DNA antibody production in vitro but also accelerates *autoimmune* *response* in vivo in MRL/+/+(MRL/n): mice which are the substrain of autoimmune MRL/lpr/lpr (MRL/l) mice. To investigate whether rNuc can induce *autoimmune* *response* similarly in naive mice, we carried out intraperitoneal (i.p.) injection of rNuc (5 mug) without adjuvant into 8-week-old female BALB/c mice...
...the mice began to show IgG hypergammaglobulinemia (HG) followed by elevation of a number of autoantibodies of the IgG class such as anti-double-stranded (*ds*) *DNA*, anti-U1 ribonuclear protein (RNP), anti-ssB(La) and anti-Fc antibodies (RF), but not by anti-Sm antibodies. However, the IgG anti-dsDNA antibody...
?ds

Set	Items	Description
S1	2608	(DS (W) (RNA OR DNA OR OLIGONUCLEOTIDE OR POLYNUCLEOTIDE OR PLASMID))
S2	3	S1 AND (MHC (W) GENE)
S3	1	RD (unique items)
S4	120	S1 AND (TAP-1 OR TAP-2 OR PKR OR IFNBETA OR MAP OR JAK OR -STAT)
S5	0	S4 AND (ANITGEN (W) PRESENTATION)
S6	0	S4 AND (ANTIGEN (W) PRESENTATION)
S7	0	S4 AND (AUTOIMMUNE (W) DISEASE)
S8	0	S4 AND (AUTOIMMUNE)
S9	0	S4 AND (IMMUNE (W) RECOGNITION)
S10	0	S4 AND ((ABERRANT OR ENHANCED) (W) (EXPRESSION))
S11	0	S4 AND (THYROID OR THYROCYTE)
S12	4	S1 AND (ANTIGEN (W) PRESENTING (W) CELL?)
S13	2	RD (unique items)
S14	8	S1 AND (AUTOIMMUNE (W) RESPONSE)
S15	5	RD (unique items)

?s s1 and (antigen (w) presentation)

	2608	S1
	839168	ANTIGEN
	192579	PRESENTATION
	19481	ANTIGEN(W)PRESENTATION
S16	5	S1 AND (ANTIGEN (W) PRESENTATION)

?rd
...completed examining records

S17 3 RD (unique items)
?t s17/3,k/all

17/3,K/1 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

09905346 99160629
Maturation, activation, and protection of dendritic cells induced by double-stranded RNA.
Cella M; Salio M; Sakakibara Y; Langen H; Julkunen I; Lanzavecchia A
Basel Institute for Immunology, CH-4005 Basel, Switzerland. cella@bii.ch
Journal of experimental medicine (UNITED STATES) Mar 1 1999, 189 (5) p821-9, ISSN 0022-1007 Journal Code: I2V
Languages: ENGLISH
Document type: JOURNAL ARTICLE

... cytokines or for conserved patterns characteristic of infectious agents. Here, we show that human DCs are activated by influenza virus infection and by double-stranded (*ds*)*RNA*. This activation results not only in increased *antigen* *presentation* and T cell stimulatory capacity, but also in resistance to the cytopathic effect of the virus, mediated by the production of type I interferon, and...
; *Antigen* *Presentation*; Autocrine Communication; Cytopathogenic Effect, Viral; Dendritic Cells--Virology--VI; Histocompatibility Antigens Class I--Immunology--IM; Interferon-alpha--Biosynthesis--BI; Lymphocyte Transformation; Major Histocompatibility Complex--Immunology...

17/3,K/2 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

12310809 BIOSIS NO.: 200000068676
DNA and RNA-based vaccines: Principles, progress and prospects.
AUTHOR: Leitner Wolfgang W; Ying Han; Restifo Nicholas P(a)
AUTHOR ADDRESS: (a)National Cancer Institute, National Institutes of Health, Building 10, Bethesda, MD**USA
JOURNAL: Vaccine 18 (9-10):p765-777 Dec. 10, 1999
ISSN: 0264-410X
DOCUMENT TYPE: Literature Review
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

...ABSTRACT: transfected with 'self-replicating' vectors briefly produce large amounts of antigen before undergoing apoptotic death. This death is a likely result of requisite double-stranded (*ds*) *RNA* intermediates, which also have been shown to super-activate DC. Thus, the enhanced immunogenicity of 'self-replicating' genetic vaccines may be a result of the...
MISCELLANEOUS TERMS: *antigen* *presentation*;

17/3,K/3 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

07615057 EMBASE No: 1999091629
Activation of target-tissue immune-recognition molecules by double-stranded polynucleotides
Suzuki K.; Mori A.; Ishii K.J.; Saito J.; Singer D.S.; Klinman D.M.; Krause P.R.; Kohn L.D.
K. Suzuki, Division of Viral Products, Ctr. for Biologics/Evaluation Res., Food and Drug Administration, Bethesda, MD 20892 United States
AUTHOR EMAIL: lenk@bdg10.niddk.nih.gov

Proceedings of the National Academy of Sciences of the United States of America (PROC. NATL. ACAD. SCI. U. S. A.) (United States) 02 MAR 1999
, 96/5 (2285-2290)
CODEN: PNASA ISSN: 0027-8424
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 39

...We show that the ability of a virus or a tissue injury to increase MHC gene expression is duplicated by any fragment of double-stranded (*ds*) *DNA* or dsRNA introduced into the cytoplasm of nonimmune cells. Activation is sequence- independent, is induced by ds polynucleotides as small as 25 bp in length...
MEDICAL DESCRIPTORS:
autoimmunity; gene expression; cell activation; single strand conformation polymorphism; *antigen* *presentation*; gene therapy; enzyme activity; major histocompatibility complex; cytoplasm; article; priority journal
?ds

```
Set     Items   Description
S1       2608   (DS (W) (RNA OR DNA OR OLIGONUCLEOTIDE OR POLYNUCLEOTIDE OR
             PLASMID))
S2          3   S1 AND (MHC (W) GENE)
S3          1   RD (unique items)
S4        120   S1 AND (TAP-1 OR TAP-2 OR PKR OR IFNBETA OR MAP OR JAK OR -
            STAT)
S5          0   S4 AND (ANITGEN (W) PRESENTATION)
S6          0   S4 AND (ANTIGEN (W) PRESENTATION)
S7          0   S4 AND (AUTOIMMUNE (W) DISEASE)
S8          0   S4 AND (AUTOIMMUNE)
S9          0   S4 AND (IMMUNE (W) RECOGNITION)
S10         0   S4 AND ((ABERRANT OR ENHANCED) (W) (EXPRESSION))
S11         0   S4 AND (THYROID OR THYROCYTE)
S12         4   S1 AND (ANTIGEN (W) PRESENTING (W) CELL?)
S13         2   RD (unique items)
S14         8   S1 AND (AUTOIMMUNE (W) RESPONSE)
S15         5   RD (unique items)
S16         5   S1 AND (ANTIGEN (W) PRESENTATION)
S17         3   RD (unique items)
?s s1 and (non (w) specific (w) sequence)
          2608  S1
       3346603  NON
       1974186  SPECIFIC
       1129368  SEQUENCE
            22  NON(W)SPECIFIC(W)SEQUENCE
    S18      0  S1 AND (NON (W) SPECIFIC (W) SEQUENCE)
?s s1 and (vaccine or treatment or immunotherapy)
          2608  S1
        184950  VACCINE
       3375384  TREATMENT
         78707  IMMUNOTHERAPY
    S19   355  S1 AND (VACCINE OR TREATMENT OR IMMUNOTHERAPY)
?rd
...examined 50 records  (50)
...examined 50 records  (100)
...examined 50 records  (150)
...examined 50 records  (200)
...examined 50 records  (250)
...examined 50 records  (300)
...examined 50 records  (350)
...completed examining records
    S20   203  RD (unique items)
?s s20 and (enhanced (w) immune (w) response)
          203  S20
       535608  ENHANCED
       948169  IMMUNE
```

```
        2214457  RESPONSE
            241  ENHANCED(W)IMMUNE(W)RESPONSE
    S21       0  S20 AND (ENHANCED (W) IMMUNE (W) RESPONSE)
?s s20 and (review)
            203  S20
        1091366  REVIEW
    S22       4  S20 AND (REVIEW)
?t s22/3,k/all

 22/3,K/1     (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2000 Dialog Corporation. All rts. reserv.

08982127   97023541
 Transverse myelopathy in SLE: clinical features and functional outcomes.
  Chan KF; Boey ML
  Department of Rehabilitation Medicine, Tan Tock Seng Hospital, Singapore.
  Lupus (ENGLAND)   Aug 1996,  5 (4) p294-9,  ISSN 0961-2033
Journal Code: BRN
  Languages: ENGLISH
  Document type: JOURNAL ARTICLE; REVIEW; REVIEW, MULTICASE

  ... one of neurogenic bladder were reported early in the diagnosis of SLE
(median of two years). Neurogenic bowel and bladder and presence of ANA and
*ds*-*DNA* were invariable. Urodynamics assessment in six patients showed
abnormal detrusor behavior in all. CT scans and myelograms were
uninformative and CSF studies were normal. ESR and complement levels were
insensitive as markers of disease activity. The *treatment* regimens
included pulses of methylprednisolone and/or cyclophosphamide followed by
prednisolone and high dose prednisolone from onset. The functional outcomes
were uniformly good-with independent...

... range of three to 45 days) whilst only two were referred for inpatient
rehabilitation. Bladder abnormalities persisted despite motor recovery and
would require long-term *review*.
  ...;  Methylprednisolone--Therapeutic Use--TU; Middle Age; Myelitis,
Transverse--Drug Therapy--DT;  Myelitis, Transverse--Rehabilitation--RH;
Paraplegia--Etiology--ET;  Prednisone--Therapeutic Use--TU; Quadriplegia
--Etiology--ET; *Treatment* Outcome; Urodynamics


 22/3,K/2     (Item 1 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

12310809   BIOSIS NO.: 200000068676
DNA and RNA-based vaccines: Principles, progress and prospects.
AUTHOR: Leitner Wolfgang W; Ying Han; Restifo Nicholas P(a)
AUTHOR ADDRESS: (a)National Cancer Institute, National Institutes of
  Health, Building 10, Bethesda, MD**USA
JOURNAL: Vaccine  18 (9-10):p765-777 Dec. 10, 1999
ISSN: 0264-410X
DOCUMENT TYPE: Literature Review
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

ABSTRACT: DNA vaccines were introduced less than a decade ago but have
  already been applied to a wide range of infectious and malignant
  diseases. Here we *review* the current understanding of the mechanisms
  underlying the activities of these new vaccines. We focus on recent
  strategies designed to enhance their function including the...

...transfected with 'self-replicating' vectors briefly produce large
  amounts of antigen before undergoing apoptotic death. This death is a
  likely result of requisite double-stranded (*ds*) *RNA* intermediates,
```

which also have been shown to super-activate DC. Thus, the enhanced immunogenicity of 'self-replicating' genetic vaccines may be a result of the...
DESCRIPTORS:
CHEMICALS & BIOCHEMICALS: ...*vaccine*; ...

...*vaccine*;

22/3,K/3 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

09497702 BIOSIS NO.: 199497506072
African horse sickness virus structure.
AUTHOR: Roy Polly(a); Mertens Peter P C; Casal Ignacio
AUTHOR ADDRESS: (a)Sch. Public Health, Univ. Alabama at Birmingham, 408 Tidwell Hall, 720 South 20th Street, Birmin**USA
JOURNAL: Comparative Immunology Microbiology and Infectious Diseases 17 (3-4):p243-273 1994
ISSN: 0147-9571
DOCUMENT TYPE: Literature Review
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English; French

...ABSTRACT: VP3 and VP7, and three minor proteins, VP1, VP4 and VP6. Within the core is the virus genome. This genome consists of 10 double-stranded (*ds*) *RNA* segments of different sizes, three large, designated L1-L3, three medium, M4-M6, and four small, S7-S10. In addition to the seven structural proteins...

...S8 and S10) and the predicted amino acid sequences of the encoded gene products are also available, mainly representing one serotype, AHSV-4. In this *review* the properties of the AHSV genes and gene products are discussed. The sequence and hybridization analyses of the different AHSV dsRNA segments indicate that the...

...have been purified and used to raise antisera in rabbits. The VP2 antisera neutralize virus infections in vitro indicating the importance of this protein for *vaccine* development.
MISCELLANEOUS TERMS: ...*VACCINE* ANTIGEN POTENTIAL

22/3,K/4 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

02186400 EMBASE No: 1982103536
A brief *review* of the development of diagnostic methods in systemic lupus erythematosus
Wen-cheng Wang; Fang R.C.Y.; Shou-hwa Han
Sect. Clin. Immunol., Dept. Med., Veter. Gen. Hosp., Taipei Taiwan
Chinese Medical Journal (Taipei) (CHIN. MED. J. TAIPEI) (Taiwan) 1981 , 28/5 (477-488)
CODEN: CIHCD
DOCUMENT TYPE: Journal
LANGUAGE: CHINESE SUMMARY LANGUAGE: ENGLISH

A brief *review* of the development of diagnostic methods in systemic lupus erythematosus

...the basis of immunological laboratory data which can be classified as seroimmunologic findings and immunopathologic findings. In seroimmunology, there which cannot fulfil for FANA, anti-*ds* *DNA*, LE cell preparation, anti-ENA, anti-Sm, complements, etc. In immunopathology, immunofluorescent

examination of renal and non-lesional skin biopsies is the main test. There
...
...name of SLE is ugly to Chinese patients. It is difficult to cure. A patient generally reacts with psychological shock to an SLE diagnosis. The *treatment* of SLE is usually carried out with immunosuppressive agents such as steroids over a long time. The complications from immunosuppressive *treatment* can cause grave consequences in the patient. Therefore, the diagnosis of SLE in patients should be made with great care, without mistakes or delays. The...

...ARA Criteria or the VGH Eight-Point Criteria, or a positive finding in one or more items in the following: FANA, LE clot test, anti-*ds* *DNA*, decreased C3 or C4, anti-Sm, LBT, and immunofluorescent examination of renal biopsy. Lastly, the possibilities of other different diagnoses are excluded.
?ds

```
Set     Items   Description
S1       2608   (DS (W) (RNA OR DNA OR OLIGONUCLEOTIDE OR POLYNUCLEOTIDE OR
             PLASMID))
S2          3   S1 AND (MHC (W) GENE)
S3          1   RD (unique items)
S4        120   S1 AND (TAP-1 OR TAP-2 OR PKR OR IFNBETA OR MAP OR JAK OR -
            STAT)
S5          0   S4 AND (ANITGEN (W) PRESENTATION)
S6          0   S4 AND (ANTIGEN (W) PRESENTATION)
S7          0   S4 AND (AUTOIMMUNE (W) DISEASE)
S8          0   S4 AND (AUTOIMMUNE)
S9          0   S4 AND (IMMUNE (W) RECOGNITION)
S10         0   S4 AND ((ABERRANT OR ENHANCED) (W) (EXPRESSION))
S11         0   S4 AND (THYROID OR THYROCYTE)
S12         4   S1 AND (ANTIGEN (W) PRESENTING (W) CELL?)
S13         2   RD (unique items)
S14         8   S1 AND (AUTOIMMUNE (W) RESPONSE)
S15         5   RD (unique items)
S16         5   S1 AND (ANTIGEN (W) PRESENTATION)
S17         3   RD (unique items)
S18         0   S1 AND (NON (W) SPECIFIC (W) SEQUENCE)
S19       355   S1 AND (VACCINE OR TREATMENT OR IMMUNOTHERAPY)
S20       203   RD (unique items)
S21         0   S20 AND (ENHANCED (W) IMMUNE (W) RESPONSE)
S22         4   S20 AND (REVIEW)
?s au=(Kohn, l?) or (kohn l?)
              0  AU=KOHN, L?
              0  KOHN L?
     S23      0  AU=(KOHN, L?) OR (KOHN L?)
?s au=(kohn, leonard) or (kohn leonard)
              0  AU=KOHN, LEONARD
              0  KOHN LEONARD
     S24      0  AU=(KOHN, LEONARD) OR (KOHN LEONARD)
?s au=(suzuki, k?) or (suzuki k?)
              0  AU=SUZUKI, K?
              3  SUZUKI K?
     S25      3  AU=(SUZUKI, K?) OR (SUZUKI K?)
?rd
...completed examining records
     S26      3  RD (unique items)
?t s26/3,k/all
```

26/3,K/1 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

09429229 98141341
Twenty five years of the "psychosine hypothesis": a personal perspective of its history and present status.

Suzuki K
Neuroscience Center, Department of Neurology and Psychiatry, University of North Carolina School of Medicine, Chapel Hill 27599, USA.
Neurochemical research (UNITED STATES) Mar 1998, 23 (3) p251-9, ISSN 0364-3190 Journal Code: NX9
Languages: ENGLISH
Document type: BIOGRAPHY; HISTORICAL ARTICLE; JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

Named Person: *Suzuki K*

26/3,K/2 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2000 Dialog Corporation. All rts. reserv.

08184159 94293041
Saul R. Korey Lecture. Molecular genetics of Tay-Sachs and related disorders: a personal account.
Suzuki K
Department of Neurology and Psychiatry, University of North Carolina School of Medicine, Chapel Hill 27599-7250.
Journal of neuropathology and experimental neurology (UNITED STATES) Jul 1994, 53 (4) p344-50, ISSN 0022-3069 Journal Code: JBR
Contract/Grant No.: R01-NS-28997, NS, NINDS; R01-NS-24289, NS, NINDS; P30-HD-03110, HD, NICHD
Languages: ENGLISH
Document type: BIOGRAPHY; HISTORICAL ARTICLE; JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

Named Person: *Suzuki K*

26/3,K/3 (Item 3 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2000 Dialog Corporation. All rts. reserv.

01778830 68243818
[Reminiscences of Professor Kiyoshi Suzuki]
Yamagata K
Kaibogaku zasshi (JAPAN) Aug 1 1967, 42 (4) p275-7, Journal Code: 09W
Languages: JAPANESE
Document type: BIOGRAPHY; HISTORICAL ARTICLE; JOURNAL ARTICLE

Named Person: *Suzuki K*
?ds

Set	Items	Description
S1	2608	(DS (W) (RNA OR DNA OR OLIGONUCLEOTIDE OR POLYNUCLEOTIDE OR PLASMID))
S2	3	S1 AND (MHC (W) GENE)
S3	1	RD (unique items)
S4	120	S1 AND (TAP-1 OR TAP-2 OR PKR OR IFNBETA OR MAP OR JAK OR -STAT)
S5	0	S4 AND (ANITGEN (W) PRESENTATION)
S6	0	S4 AND (ANTIGEN (W) PRESENTATION)
S7	0	S4 AND (AUTOIMMUNE (W) DISEASE)
S8	0	S4 AND (AUTOIMMUNE)
S9	0	S4 AND (IMMUNE (W) RECOGNITION)
S10	0	S4 AND ((ABERRANT OR ENHANCED) (W) (EXPRESSION))
S11	0	S4 AND (THYROID OR THYROCYTE)
S12	4	S1 AND (ANTIGEN (W) PRESENTING (W) CELL?)
S13	2	RD (unique items)
S14	8	S1 AND (AUTOIMMUNE (W) RESPONSE)
S15	5	RD (unique items)